Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
BUSINESS
Ranitidine Compensation Programs Draw Complaints from Pharmacists, Separate Billing Seen “Unrealistic”
Treading in the footsteps of GlaxoSmithKline, generic manufacturers of ranitidine in Japan have started their own compensation programs to cover the costs of drugs prescribed as substitutes for the heartburn medicine, which is now being recalled over carcinogen concerns. However,…
To read the full story
Related Article
- GSK Japan to Pull Prescribed Zantac and Compensate for Substitutes; Generic Peers Follow
October 11, 2019
- GSK Japan Ups Recall Level for Zantac to “Class I”
October 10, 2019
- All 11 Manufacturers Pull Ranitidine from Shelves, “Class I” Recalls for 9 Firms
October 4, 2019
- GSK Recalls Zantac as Preventive Measure for NDMA Carcinogenic Risk
September 30, 2019
- MHLW Asks 15 Makers to Investigate Ranitidine, Nizatidine for Potential Carcinogen Contamination
September 20, 2019
BUSINESS
- Negative Impact of Rumors on Kostaive Is Immense: Meiji Pharma President
October 9, 2024
- Pfizer Curbs Supply of Avastin Biosimilar, 2 Others Hit by Knock-On Effect
October 9, 2024
- Eisai Eyes 2 Trillion Yen Sales Mark by FY2032 with Leqembi as Driver
October 9, 2024
- Eisai’s Gout Drug Urece Approved in Thailand
October 9, 2024
- Astellas, AviadoBio Sign Dementia Gene Therapy Deal
October 9, 2024
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…